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Objectives: This study characterises pharmacologically the angiotensin II receptor in experimental vein grafts and 
examines the effect of the angiotensin II receptor (type 1) antagonist (L158,809) on the formation of vein graft intimal 
hyperplasia in vivo, as well as the in vitro physiological response to angiotensin II of vein grafts after chronic oral 
L158,809 treatment. 
Materials: Thirty New Zealand White rabbits had a right carotid interposition bypass graft using the external jugular 
vein and were killed on the 28th postoperative day. 
Design: To characterise the angiotensin II receptors, concentration response curves to angiotensin II were obtained in vitro 
in the presence or absence of L158,809. To determine the effect of L158,809 on the development ofintimal hyperplasia, 10 
animals received chronic oral therapy with L158,809 (IOmg/kg/day; begun 5 days before surgery and continued until 
harvest) and 10 animals received vehicle only as controls. These grafts were harvested either for histology (n = 6 per group) 
or for in vitro isometric tension studies to angiotensin II. 
Results: The monophasic ontractile response to angiotensin II in the untreated vein grafts could be inhibited in a 
concentration dependent manner by L158,809 with first order kinetics. Chronic oral treatment with L158,809 produced a
48% decrease in intimal thickness from 82 + ll~m (mean + S.E.M.) in the controls to 43 + 7t~m in the treated vein grafts 
(p = 0.002). There was also a significant decrease (45%) in the medial thickness between the control (76 + 61~m) and 
LI58,809 treated (42 + 61~m) vein grafts (p = 0.007). The responses to angiotensin II were abolished in the vein grafts by 
chronic L158,809 therapy. 
Conclusions: This study suggests that vein graft angiotensin II responses are mediated through a type 1 receptor and that 
chronic inhibition with L158,809, significantly reduces intimal hyperplasia nd medial hypertrophy in experimental vein 
grafts and concomitantly abolishes the in vitro responses to angiotensin II. Therefore, angiotensin II acting through AT1 
receptors mediates a significant part of the intimal hyperplastic response in vein grafts. 
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Introduction 
A continuing problem of the saphenous vein bypass 
graft is the development of intimal hyperplasia which 
results in either graft dysfunction or graft failure. 1'2 
There has, therefore, been considerable interest in 
obtaining therapeutic control of intimal hyperplasia 
before the lesion threatens the patency of the graft. 3
The development of vein graft intimal hyperplasia is
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associated with alterations in the physiological 
responses of the graft's endothelial and smooth 
muscle cells. These changes in physiological pheno- 
type are manifested by changes in the contractile and 
relaxant properties of the cells. 2 In particular, 
Yesponses to angiotensin II in the arterial vein grafts 
are markedly altered. 4 There is an increase in both the 
sensitivity and the maximal contractile responses and 
the loss of the triphasic dose response curve generated 
in response to angiotensin II in the vein after a vein is 
inserted into the arterial circulation. Further studies 
have shown that the induction of altered angiotensin 
II responses occurs within the first 7 days of vein 
grafting and that by 28 days, vein grafts are more 
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sensitive to angiotensin II than the carotid vessels into 
which they are placed. 5
This study characterises pharmacologically the 
angiotensin II receptor in experimental vein grafts and 
examines the effect of a novel and potent angiotensin 
II receptor antagonist (L158,809) on the formation of 
vein graft intimal hyperplasia in vivo, as well as the in 
vitro physiological response to angiotensin II of vein 
grafts from animals treated with the receptor antago- 
nist L158,809. 
Material and Methods 
Thirty New Zealand White rabbits weighing 2.0-2.5 
kg underwent right common carotid artery bypass 
grafting using the ipsilateral external jugular veins as 
previously described. 6 The animals were randomly 
allocated to the control (n=20) or experimental 
(n--10) groups preoperatively. The experimental 
group received L158,809. (5,7-dimethyl-(2-ethyl- 
3[[2'-(1H-tetrasol-5-371)[1,1']-biphenyl-4-yl]methyl]-3H- 
imidazo[4,5-b] pyridine; a specific angiotensin II 
antagonist; 10 mg/kg/day, Merck Company, West 
Point, PA, U.S.A.) in their drinking water (200 ml/ 
day) for 5 days prior to surgery, and thereafter until 
harvest. All animals were sacrificed with an overdose 
of barbiturates 28 days after the operation. At opera- 
tion and at harvest, the arterial pressure of all animals 
was measured through a cannula placed in the middle 
ear artery with a pressure transducer (Viggo Spec- 
tramed, Oxnard, CA, U.S.A.) connected to a Mennen 
Patient Monitor (MR1300, Mennen Medical Inc., Clar- 
ence, NY, U.S.A.). Animal care complied with the 
"Principles of Laboratory Animal Care" as formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
issued by the National Institutes of Health. (U.S. 
Department of Health and Human Services, NIH 
Publication No. 80-23, revised 1985). 
Morphologic studies 
Following isolation and heparinisation (200 IU/kg, 
i.v.), six control and six experimental grafts were 
perfusion fixed in situ at 80ram Hg with a standar- 
dised initial infusion of Hanks Balanced Salt Solution 
(HBSS, Gibco Laboratories, Life Technologies Inc., 
Grand Island, NY, U.S.A.) followed by 2% glutar- 
aldehyde made up in 0.1M cacodylate buffer (pH 7.2) 
supplemented with 0.1M sucrose to give an osmolality 
of approximately 300mOsm. After immersion in the 
fixative for 48 h, the graft was divided into a proximal, 
middle and distal third and cross-sections from the 
mid-part of each third was taken for processing. 
Following standard procedures, the specimens were 
stained with a modified Masson's trichrome and 
Verhoeff's elastin stain. 22 The lumen, intima and the 
media were defined and their dimensions (area and/ 
or thickness) calculated by videomorphometry (Inno- 
vision 150, American Innovision Inc., San Diego, CA, 
U.S.A.). A ratio of the intima and media areas was 
calculated (intimal ratio = intimal area/[intimal +me- 
dial areas]). A ratio of the intimal and medial areas 
(intimal ratio = intimal area/[intimal +medial areas]) 
and a luminal diameter to cross-sectional wall thick- 
ness (luminal index = luminal diameter/[cross-sec- 
tional wall thickness]) was also calculated. For scan- 
ning electron microscopy (s.E.M.), mid-portion 
specimens of the glutaraldehyde-fixed grafts were 
rinsed with the same buffer solution as described 
above, dehydrated in ascending concentrations of 
ethanol, transferred to absolute acetone, critical point 
dried from CO2, mounted on specimen stubs and 
sputter-coated with gold-palladium according to stan- 
dard techniques. All specimens were examined in a 
Philips 500 scanning electron microscope (N.V. Phil- 
ips, Eindhoven, The Netherlands) at an accelerating 
voltage of 12 or 20kV. For transmission electron 
microscopy (TEM), representative s ctions from the 
mid-portion of the glutaraldehyde-fixed grafts were 
post-fixed for i h at room temperature in 1% osmium- 
tetroxide dissolved in the same cacodylate buffer as 
used for the glutaraldehyde solution. After dehydra- 
tion in ascending concentrations of ethanol the 
specimens were transferred to propylene oxide and 
finally embedded in Epon 812 monomer. Polymer- 
isation was carried out overnight at 40°C followed by 
2 days at 60°C. Ultrathin sections were cut with a 
diamond knife on a Reichart ultramicrotome (Reichart 
Optische Werke AG, Vienna, Austria), contrasted with 
uranyl acetate and lead citrate, and then examined in 
a Philips 300 transmission electron microscope (N.V. 
Philips, Eindhoven, The Netherlands) both operated 
at 60kV. 
Physiological studies 
For isometric tension studies, vessels were sectioned 
in situ into four 5mm segments, excised and each ring 
was immediately mounted between two stainless teel 
hooks in 5 ml organ baths containing oxygenated 
Krebs solution (122 mM NaC1, 4.7 mM KC1, 1.2 mM 
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KC1, 1.2 mM MgC12, 2.5 mM CaC12, 15.4 mM NaHCO3, 
1.2 mM KH2PO 4 and 5.5 mM glucose, maintained at 
37°C and oxygenated with 95% 02 and 5% CO2) as 
previously described. 6 Following equilibration, the 
resting tension was adjusted in increments from 0.5 to 
2.5 g and the maximal response to a modified 
oxygenated Krebs solution containing 60 mM KC1, 66.7 
mM NaC1, 1.2 mM MgC12, 2.5 mM CaC12, 15.4 mM 
NaHCO3, 1.2 mM KH2PO 4 and 5.5 mM glucose was 
measured to establish a length-tension relationship. 
The tension at which a ring generated its maximal 
contractile response to the modified Krebs solution 
was considered the optimal resting tension for that 
particular ing and the ring was set at this tension for 
subsequent studies. The tissue was allowed to re- 
equilibrate for a minimum of 30 min between each 
experimental run. All drugs were obtained from 
Sigma Chemical Co. (St Louis, MO, U.S.A.). 
To determine the effect of L158,809 on the angio- 
tensin II responses of untreated vein grafts, rings from 
untreated vein grafts (n = 10) were incubated for 30 
min in increasing concentrations of L158,809 (10 -12 to 
10-4 M). Cumulative dose response curves to angio- 
tensin II (10 -9 to 10 -5 M) were determined at each 
concentration. To determine the effect of chronic oral 
therapy with L158,809 on vein graft contractile and 
relaxant functions, physiological responses of jugular 
veins (n = 4 per group) and vein grafts (n = 4 per 
group) from both treated and untreated animals were 
studied. Cumulative dose response curves to angio- 
tensin II (10 -9 to 10 -5 M), norepinephrine (10 -9 to 10-4 
M), bradykinin (10 -9 to 10 -5 M) and serotonin (10 -9 to 
10-4 M) were performed. After precontraction with 
norepinephrine (concentration that produces 75% 
maximal contraction), relaxation in response to acet- 
ylcholine (10 -8 to 10-4 M) and sodium nitroprusside 
(10 -8 to 10-4 M) were determined. 
In vitro DNA synthesis and cell proliferation studies 
Vascular smooth muscle cells from the media of the 
thoracic aorta of male New Zealand White rabbits 
were isolated and grown in tissue culture as pre- 
viously described. Cells in the 6th through 8th 
passages were used for these experiments. Confluent 
cells in 75 cm 2 culture flasks (Falcon Plastics, Lincoln 
Park, NJ, U.S.A.) were washed twice with 8 ml 
phosphate buffered saline (Gibco Laboratories, Grand 
Island, NY, U.S.A.) followed by trypsinization for 7 
rain at 37°C with 8 ml trypsin/EDTA solution (Gibco). 
Three millilitres of Dulbecco's minimal essential 
medium (Gibco) with 10% fetal calf serum (Gibco) was 
then added to inactivate the trypsin. The cells were 
isolated by centrifugation (250g for 10 min) and 
resuspended in Dulbecco's minimal essential medium 
with 10% fetal calf serum (growth medium, Gibco) 
containing penicillin (100 IU/ml), streptomycin 
(100/zg/ml) and amphotericin B (125pg/ml). 
[H 3] thymidine incorporation: Culture wells (6-well 
cluster dishes, 35mm diameter; Falcon Plastics) were 
inoculated with 3ml growth medium containing 
5 x 104 cells. The growth medium was replaced with 
new medium every third day until the cells reached 
confluency as judged by microscopic examination. 
The cells grew in hills and valleys typical of vascular 
smooth muscle cells. On reaching confluency, the 
medium was not changed for 3 days to induce a 
quiescent state in the cells. On the day of the 
experiment, new growth medium was exchanged 2 h 
and again 1 h before the initiation of the experiment. 
The experiments were initiated by exchanging the 
growth medium with new medium containing 4/~Ci 
[H3]-thymidine (2 Ci/mM; ICN, Irvine, CA, U.S.A.) 
with and without the angiotensin II antagonist 
(L158,809; 10 -9 to 10 -4 M). Incorporation of [H3]-thymi - 
dine into acid-precipitable material was measured 
after a 24 h incubation period (air plus 5% CO2 at 
37°C). At harvest, the dishes were placed on ice and 
each well was washed twice with 3 ml of ice cold 
Dulbecco's phosphate-buffered saline (Gibco). Three 
millilitres ice cold 5% trichloracetic acid was added. 
After 15 min, the acid was removed and each well 
washed with 4 ml ice cold water. Sodium hydroxide 
(lml, 0.2N) was then added and the dishes were 
incubated for 20 min at 37°C. Aliquots (100/~1) of the 
sodium hydroxide solution were counted in 10 ml 
Lefko-fluor (Research Products International Corp., 
Mount Prospect, IL, U.S.A.) by a Packard Tri-carb 4530 
scintillation counter (Packard Instruments Inc., Down- 
ers Grove, IL, U.S.A.). Results are expressed as 
percentage of control. 
Cell proliferation: Culture wells (6-well cluster dishes, 
Falcon) were inoculated with 3ml growth medium 
containing 5 x 104 cells and allowed to attach over 
night. Cell proliferation was assessed in the absence of 
and in the presence of three concentrations of the 
angiotensin II antagonist (L158,809): 10-6M, 10-5M and 
10-4M. The compound was added to the culture media 
from the second day. Cell counts were determined on 
day 1, 2, 3, 4, 5, 6, 8 and 12. Cells from each well were 
removed by trypsinisation and then microscopically 
counted using a blood cell hemocytometer (Improved 
Neubauer Hemacytometer, 0.1mm deep, AO, Buffalo, 
NY, U.S.A.). There were three wells for each group per 
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day and for each well, two cell counts were averaged 
and only accepted as accurate if the counts were 
within 10% of each other. The cell counts were then 
averaged to produce the mean cell count for each 
experimental group for each day. 
Data and statistical analysis 
Results 
The isometric responses of the vessel rings were 
converted to percent maximal response and plotted 
against he negative logarithm of the agonist dose to 
produce concentration response curves. The ECso 
value, the concentration for the half maximal 
response, for each agonist in each ring was calculated 
by logistic analysis and is expressed as the pD2 which 
is defined as -lOgl0[ECs0].7 Schild's plot was calculated 
as described by Kenakin. 8 The maximal contractile 
response of each ring to each agonist is expressed in 
milligrams of force developed and is then standar- 
dised to a contractile ratio (contractile ratio = actual 
maximal contraction of an agonist/actual maximal 
contraction to 60mM KC1). All data are presented as 
the mean + S.E.M. and statistical differences between 
groups were tested with a one way analysis of 
variance (ANOVA) for the functional and in vitro 
studies and with a Mann-Whitney Rank Sum test for 
the morphometric data. A p-value less than 0.05 is 
regarded as significant. 
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In Vitro studies 
Functional responses in the presence of L158,809: 
Untreated vein grafts responded with a monophasic 
contractile response to angiotensin II. This response 
could be inhibited in a concentration dependent 
manner by increasing concentrations of the com- 
petitive antagonist to the AT1 receptor subtype: 
L158,809 (Table 1). The response was abolished at 
10-6M L158,809. Antagonism with increasing concen- 
trations of L158,809 (10-12M to 10~M) showed pro- 
gressive inhibition of the angiotensin II responses (Fig. 
1A) and exhibited first order kinetics (Fig. 1B; Schild 
plot slope = 0.97; 1.2 = 0.82). 
In vitro [H 3] thymidine incorporation and cell proliferation 
L158,809 did not inhibit the in vitro incorporation of 
[H 3] thymidine into the DNA of serum-stimulated 
cultured rabbit aortic smooth muscle cells (Fig. 2A). 
Table 1. Responses to angiotensin II in vein grafts in the preseno 
of L158,809 
L158,809 (M) Sensitivity to Angiotensin II 
Control 6.72+0.41 
10 -~z 6.64+0.53 
10- ]1 6.34+0.24 
10 -]° 5.99+0.24 
10 -9 5.81_+0.43 
10 -8 5.71+0.32 
10 -7 4.96+0.29 
10 -6 No response 
10 4 No response 
Sensitivities of the cumulative dose response curves to angiotensin I 
in the presence of increasing concentrations of L158,809. Thq 
sensitivity or the ECs0 value, the concentration for the half maxima 
response, for each agonist in the presence or absence of th~ 
antagonist was calculated by logistic analysis and is expressed as - 
lOgl0 [ECs0 ]. Values are the mean + S.E.M. of the -log10 [ECs0 ]. 
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Fig. 1. (A) Cumulat ive dose response curves to angiotensin II [©] 
and in the presence of increasing concentrations of L158,809 (10 -~2 
[@], 10 -l° [ES], 10 ~s tin], 10 4 [A]). Values are the mean + S.E.M. 
percent maximal contraction. (B) Schild's plot for angiotension II in 
the presence of increasing concentrations of L158,809 (10 12M to 
6 10- M). Values are the mean _+ S.E.M. 
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Incubat ion of smooth muscle cell cultures with 
increasing concentrat ions of L158,809 (10-6M, 10-5M 
and 10-4M) had no effect on the in vitro cellular 
prol i ferat ion in response to serum st imulat ion (Fig. 
2B). 
Chronic studies 
General: All animals  surv ived to harvest. There were 
no graft occlusions. No in vivo toxic effects of L158,809 
were noted. Mean arterial b lood pressures were 
equivalent  in both groups of animals.  At harvest, there 
were no macroscopic differences between the control 
and  L158,809 treated ve in  grafts. Microscopicall:~ the 
grafts from control animals  had a greater degree of 
int imal  hyperplas ia  than the L158,809-treated animals.  
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Fig. 2. (A) The response in vitro [SH]-thymidine incorporation i to 
the DNA of cultured rabbit vascular smooth muscle c lls in the 
presence of L158,809 (10 -9 to 10-~M). Values are the mean + S.~.M. 
percent of the control for six experiments. (B) The dose dependent 
inhibition of the in vitro proliferation of cultured rabbit vascular 
smooth muscle cells by L158,809 at three concentrations: 10~M(A), 
10-SM(O) and 10~M(I) compared to control (O). Values are the 
mean +S.E.M. of cell counts (x 103) per ml for six experiments. 
= application of L158,809 to cell culture media. 
In  l ight microscop:~ the appearance of the int imal  
hyperplas ia in the control and  exper imental  vein 
grafts was similar a l though the degree of int imal  
hyperplas ia  in the L158,809 treated ve in  grafts was 
much less (Fig. 3A). The smooth muscle cells in the 
int ima appeared to be arranged in a criss cross pattern 
with col lagen and connective tissue between these 
smooth muscle cells. The media  of the grafts from 
200 
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Control L158,809 Control L158,809 Control L158,809 
Proximal Middle Distal 
Fig. 3. (A) A composite photomicrograph showing a cross-section 
from the wall of the middle segment of a control and L158,809 
-treated vein graft, h = intimal hyperplasia, m = media. Magnifica- 
tion x 100. (B) The cross-sectional intimal thicknesses for the 
proximal, middle and distal segments of grafts from control and 
L158,809 -treated animals. Values are the meanthickness in /zm. 
There are significant differences in the thickness of the intima in all 
segments (**, proximal: p = 0.04, middle: p = 0.02 and distal: p = 0.008, 
by Mann Whitney Rank Sum Test). There are significant differences 
in the thickness of the media in all segments (##, proximal: p = 0.05, 
middle: p = 0.007 and distal: p = 0.04, by Mann Whitney Rank Sum 
Test) Intima ([:]); media (11). 
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either group was similar in appearance and contains 
layers of smooth muscle cells orientated in a circular 
pattern. On light microscop34 the media demonstrated 
morphological features of hypertrophied smooth mus- 
cle cells. SubjectivelN the degree of hypertrophy in 
these cells was less in the L158,809 treated vein 
grafts. 
Morphology: Chronic oral treatment with L158,809 
produced a 48% decrease in intimal thickness of the 
middle segments of the vein grafts from 82 + l~m 
(mean+s.E.M.) in the controls to 43+7/xm in the 
L158,809 treated vein grafts (p = 0.002). There was also 
a significant decrease (45%) in the medial thicknesses 
between the control (76 _+ 6/xm) and L158,809 treated 
(42 + 6Fzm) vein grafts (p = 0.007). With these changes 
in total wall thickness, there was only a 26% increase 
in overall luminal area of the middle segments in the 
L158,809 treated vein grafts compared to controls 
(17.6 + 1.4 vs. 13.9 + 2.0mm2; p = 0.44). Whereas the 
mean intimal thickness decreased by 42% for the 
proximal and by 36% for the distal segments (Fig. 3B), 
the mean medial thickness decreased by 30% for the 
proximal and distal segments respectively (Fig. 3B). 
Associated with these changes, the luminal areas 
increased by 54% in the proximal and by 37% for the 
distal segments of the L158,809 vein grafts compared 
to controls. In contrast, the intimal ratio changed by 
-2%, + 2% and -2% in the proximal, middle and distal 
segments respectively (Table 2). The luminal index, a 
measure of changes in luminal diameter in relation to 
total wall thickness, increased by 12% in the proximal 
and middle segments but decreased by 13% in the 
distal segments respectively with chronic oral 
L158,809 therapy (Table 2). 
The ultrastructural characteristics of the endothelial 
surfaces were examined in the scanning electron 
microscope. In both the control vein graft (Fig. 4A) 
and the L158,809 treated vein graft (Fig. 4B) the 
intimal surfaces were covered by continuous layers of 
endothelial cells which had distinct cell borders and 
were covered by numerous minute surface processes. 
Subjectively, these minute surface processes appear to 
be less in the L158,809 treated vein graft. Transmission 
electron-microscopy of the control (Fig. 4C) and the 
L158,809 treated vein grafts (Fig. 4D) showed a well 
defined monolayer of endothelial cells. Beneath the 
endothelium, both vein grafts were composed of 
multiple layers of smooth muscle cells embedded in a 
matrix of poorly developed connective tissue. The 
smooth muscle cells were both of the synthetic (i.e. the 
cytoplasm contains a large fraction of synthetic organ- 
elles) and the contractile (i.e. the cytoplasm is predom- 
inantly occupied with well organised myofilaments) 
Table 2. Dimensional analysis 
Control L158,809 p-value 
(n=6) (n=6) 
Proximal segment 
Lumen (mm 2) 13.4_+2.4 20.6_+2.8 (+54%) 0.16 
Intima (ram 2) 1.22+-0.14 0.97+-0.28 (-20%) 0.37 
Media (mm 2) 0.79+-0.08 0.67+_0.16 (-15%) 0.59 
Intimal ratio 0.60+_0.02 0.59+_0.07 (-2%) 0.95 
Luminal index 29.1+4.1 32.6+7.4 (+12%) 0.66 
Middle segment 
Lumen (mm 2) 13.9+-2 17.6+-1.4 (+26%) 0.44 
Intima (mm 2) 0.98+-0.11 0.66+-0.11 (-32%) 0.11 
Media (mm 2) 0.97+0.07 0.65_+0.11 (-33%) 0.04 
Intimal ratio 0.49_+0.03 0.50_+0.08 (+2%) 0.85 
Luminal index 29.6+3.1 33.2+-7.4 (+12%) 0.60 
Distal segment 
Lumen (mm 2) 15.04+3.2 20.5+2.0 (+37%) 0.25 
Intima (mm 2) 1.26+0.15 1.04+0.11 (- 7%) 0.25 
Media (mm 2) 0.98+0.09 0.85+_0.09 (-13%) 0.37 
Intimal ratio 0.56+0.02 0.55+_0.08 (-2%) 0.95 
Luminal index 26.2+3.2 22.8_+7.2 (-13%) 0.62 
The area of the lumen, the intimal and the medial layers from thq 
proximal, the middle and the distal segments of the control and thq 
L158,809 treated grafts. The intima ratio (intimal area/[intimal- 
medial areas]) and luminal index (luminal diameter/[cross-sectiona 
wall thickness]) are also shown. Values are the mean + S.E.M 
Percentage changes of each parameter from control are shown ii 
parentheses. The p-values are by Mann Whitney Rank Sum Test. 
phenotypes. In the intima hyperplasia little well 
defined collagen was found. Collagen was however 
prominent in the media and in the adventitia. Hyper- 
trophic medial smooth muscle cells could be found in 
the control vein grafts whereas there were no hyper- 
trophied medial smooth muscle cells found in the 
L158,809 vein graft walls. 
Physiological responses - -  Vein grafts: The L158,809 
treated grafts showed no significant differences in 
maximal contractions in response to the non-receptor 
dependent agonist, potassium chloride, compared to 
controls (900 + 20mg vs. 990 _+ 10mg respectively). In 
control vein grafts, angiotensin II produced a sigmoid 
dose response curve. This contractile response to 
angiotensin II in the treated vein graft was abolished 
by chronic L158,809 therapy (Fig. 5B; Table 3). In 
response to norepinephrine, serotonin and bradyki- 
nin, the L158,809 treated grafts and control grafts 
responded with sigmoid dose response curves and the 
sensitivities (pD2) to norepinephrine, serotonin and 
bradykinin were unchanged by treatment with 
L158,809 (Table 3). The maximal contractions gen- 
erated by the L158,809 treated grafts in response to 
norepinephrine bradykinin and serotonin, when 
adjusted to the response to potassium chloride (con- 
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tractile ratio), were equivalent to controls (Table 4). No 
precontracted control vein grafts relaxed in response 
to the endothelium dependent relaxing agent, acet- 
ylcholine. In contrast, 11 of 24 rings (46%) in the 
L158,809 treated vein grafts showed some relaxation 
in response to acetylcholine (maximal relaxation 
10 + 14%). In response to sodium nitroprusside, there 
was a marked increase in sensitivity of the L158,809 
treated vein grafts compared to control (Table 3) with 
maximal relaxations of 91+2% and 99%+10% 
respectively. 
Veins: Jugular veins from control and L158,809 treated 
animals produced sigmoid dose response curves to 
the cumulative addition of norepinephrine and brady- 
kinin. The rabbit jugular vein did not contract o 
serotonin. There was no significant changes in sensi- 
tivity (pD2) to norepinephrine and bradykinin after 
L158,809 treatment (Table 3). The responses to 60mM 
potassium chloride, a non-receptor dependent agon- 
ist, were also not different (150 + 20mg and 179 + 34mg 
for control and L158,809 treated jugular vein respec- 
tively; p = NS). The maximal contractions generated in
A B 
G 
Fig. 4. (A) Scanning electron micrograph of the endothelial lining of a control vein graft showing intact unaltered, elongated endothelial 
cells (EC) with distinct cell borders (arrowheads). There is no disruption of the endothelial lining. The white dots at the cell bodies represent 
small villi-like plasma membrane projections. Magnification × 2200. (B) Scanning electron micrograph of a L158,809-treated vein graft 
showing well preserved ndothelial cells (EC) with sharply outlined cell borders (arrowheads). The villi-like plasma membrane projections 
seem to be less prominant compared to control vein grafts. Magnification × 2200. (C) Transmission electron micrograph of a control vein 
graft. There are intact endothelial cells (EC) on the luminal surface of the vessel. Arrowheads indicate the elevated cell borders. Beneath the 
endothelium, several layers of mostly obliquely sectioned smooth muscle cells (SMC) representing intimal hyperplasia can be identified. 
These smooth muscle cells contain well defined bundles of contractile material located in their periphery. The electron dense material filling 
the intercellular spaces of the intimal hyperplasia layer appears unorganised. Voluminous' hypertrophic smooth muscle cells can be 
identified. The well organised connective tissue has been displaced to a deeper layer of the wall in this specimen. Magnification × 9500. 
(D) Transmission electron micrograph of a L158,809-treated vein graft. There are intact endothelial cells (EC) lining the intimal surface of 
the vein graft. The elevated cell borders are indicated by arrowheads. The intimal hyperplasia in this specimen is morphologically 
manifested by the multiple layers of smooth muscle cells (SMC) beneath the endothelium. Magnification × 9500. (Reproduced here at 
50%). 
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response to norepinephrine were similar to those 
recorded in the controls while those to bradykinin 
were significantly decreased (Table 4). Endothelium 
dependent relaxation was equivalent in the L158,809 
treated veins compared to the controls (Table 3). 
However, the sensitivity of the response to sodium 
nitroprusside, a non endothelium dependent relaxant 
was significantly augmented in the L158,809 treated 
jugular veins compared to the control veins (Table 3); 
maximal relaxation was equivalent (84+7% and 
88 + 10% respectively.). 
Discussion 
The presence of a local renin-angiotensin ystem in the 
vascular wall is now considered integral to vascular 
homeostasis. Many elements of this system are locally 
synthesised (i.e. renin, angiotensin I and angiotensin 
converting enzyme (ACE)), locally produced (i.e. 
angiotensin II) or locally degraded (i.e. bradyki- 
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Fig. 5. Cumulative dose response curves to angiotensin II in the 
jugular veins (A) and vein grafts (B) from control and L158,809 
treated animals. Values are the mean _+S.E.M. percent maximal 
contraction. 
Tab le  3.  Sens i t iv i ty  
Control L158,809 p-value 
Jugular vein 
Angiotensin II 6.14_+0.50 5.85_+0.32 0.61 
Norepinephrine 5.66_+0.31 6.48_+0.27 0.06 
Bradykinin 7.02_+0.19 7.31_+0.33 0.49 
Serotonin No response No response - -  
Acetylcholine 6.84+0.37 6.74-+0.15 0.77 
Sodium nitroprusside 5.77_+0.10 6.22_+0.09 0.004 
Vein graft 
Angiotensin II 6.72-+0.41 No response - -  
Norepinephrine 6.09+0.09 6.04_+0.08 0.79 
Bradykinin 5.87+0.08 5£5+0.04 0.93 
Serotonin 6.20_+0.15 6.05+0.09 0.41 
Acetylcholine No response 6.37_+0.11" - -  
Sodium nitroprusside 5.34_+0.22 6.37+0.05 0.0001 
Values are the mean _+ S.E.M of the sensitivity (pD2). The p-values arc 
by ANOVA and are compared to control vessel. 
"13 of 24 tings failed to relax. 
Tab le  4.  Max imal  phys io log ica l  responses  
Control L158,809 p-value 
Jugular vein 
Angiotensin II 0.74+_0.13 0.46+0.17 0.32 
Norepinephrine 1.13+0.25 1.06+0.12 0.77 
Bradykinin 3.88_+0.10 2.18_+0.41 0.007 
Serotonin No response No response - -  
Vein graft 
Angiotensin II 1.21+0.07 No response - -  
Norepinephrine 1.62+0.36 1.57_+0.05 0.85 
Bradykinin 0.38+0.21 0.61_+0.08 0.22 
Serotonin 0.41+0.08 0.47+0.08 0.64 
Values are the mean + S.E.M of the contractile ratio. The p-values arc 
by ANOVA and are compared to control vessel. 
nin). 9-n Local renin-angiotensin ystems are involved 
in the regulation of the cellular responses of a vessel 
wall to both haemodynamic forces and to the intimal 
injury which inevitably occurs following angioplasty 
or vein grafting. Vascular injury induces angiotensino- 
gen gene expression in the media and the neointima 
which is maximal at 7 days after the injury. 12'13 Local 
tissue ACE activity is upregulated and can be corre- 
lated with the degree of intimal hyperplasia present) 4 
In this regard, inhibition of ACE by systemic ACE 
inhibitors results in an 80% inhibition of intimal 
hyperplasia formation in balloon injured arteries and 
a 40% reduction of intimal hyperplasia development 
in vein grafts. 15"16 The rationale for the effectiveness of 
ACE inhibitors in this response to injury may lie in the 
fact that with injur)~ there is increased local activity of 
ACE which can be localised immunologicatly to the 
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smooth muscle cells of the intimal hyperplasia. 17The 
degree of intimal hyperplasia reduction can also be 
correlated with a dose dependent inhibition of local 
tissue ACE activity. 14 Clinically, the use of ACE 
inhibitors to retard vein graft intimal hyperplasia has 
not been tested but their effectiveness in reducing the 
incidence of restenosis following angioplasty has been 
unsuccessful. 18 
Theoretically, the increased levels of ACE activity in 
these vessels would provide increased local concentra- 
tions of angiotensin II. Once formed, angiotensin II
can bind to two receptor subtypes, AT1, predom- 
inantly on smooth muscle cells, and AT2, mainly on 
endothelial cells. 9 Angiotensin II is known both to 
induce smooth muscle cell hypertrophy and to stim- 
ulate cell proliferation apparently through its inter- 
action with both TGF-~ and bFGF. I~'19-21 Both AT1 and 
AT2 receptors for angiotensin II contribute to the 
intimal hyperplastic process in balloon injured arteries 
and treatment with the AT 1 receptor antagonist, 
losartan, can significantly reduce intimal proliferation 
after balloon injury in some models. 22"23 A similar 
effect with AT1 receptor antagonist, losartan, has been 
noted in an in vitro cell culture system on saphenous 
vein intimal hyperplasia. ~4 In contrast, systemic 
inhibition of AT 2 receptor does not inhibit the intimal 
proliferative response, but local infusion of an antago- 
nist into the vicinity of a balloon injured vessel will 
reduce the degree of intimal hyperplasia 
formation. 25 
The present study confirms that there is a change in 
the response of a vein to angiotensin II after insertion 
of the vein into the arterial circulation with the 
development of a monophasic ontractile response. 
Incubation with the competitive antagonist of the AT~ 
receptor subtype: L 158,809 inhibited this response in 
a concentration dependent manner with first order 
kinetics and the response was abolished after incuba- 
tion with 10-7M L158,809. Scatchard analysis has 
shown that the affinity of L158,809 for rabbit aortic 
smooh muscle cells with ICs0 of 0.3riM, 26'27 Other 
studies have shown that L158,809 acts as a com- 
petitive, high affinity antagonist of angiotensin II 
(pA2 = 10.5), that it can inhibit angiotensin II induced 
inositol phosphate accumulation in vascular smooth 
muscle cells and that it can inhibit the contractile 
responses to angiotensin II in isolated blood ves- 
sels. 26'27 Recently, Panek et al have demonstrated that 
although L158,809 is a competitive antagonist based 
on binding studies it will produce insurmountable 
antagonism of the AT 1 receptor when tested function- 
ally (due to compound sequestration i  the tissue or 
an interaction with the AT 1 receptor). 2s L158,809 has 
been shown to be very specific for the angiotensin II
receptor AT 1 and does not interact with other receptor 
systems. 26"27 The cumulative findings in the present 
study, therefore, suggest that the angiotensin II 
response in vein grafts is mediated in whole by an AT~ 
receptor. This is supported by recent work which has 
localised the AT1 receptor to the intima of the rabbit 
vein graft. 29 Expression of a receptor does not imply 
function. It appears from the results of the present 
study that this receptor is both functional and relevant 
to the development of intimal hyperplasia. 
Chronic AT1 inhibition with L158,809, significantly 
reduces intimal hyperplasia nd medial hypertrophy 
in experimental vein grafts and concomitantly abol- 
ishes the in vitro responses to angiotensin II. The 48% 
decrease in intimal hyperplasia is equivalent o the 
best results achieved with single agent therapy in 
these vein grafts (verapamil-30%, captopril-40%, ami- 
nosteroids-44%, methylaminochromans-41%, desfer- 
rioxamine-39%, L-arginine-51%). However, a unique 
feature in this experiment is the concomitant 45% 
reduction in the medial response of these vein grafts. 
Such a decrease in the medial response has not been 
documented previously. The simultaneous decreases 
in both intimal and medial dimensions explain the 
lack of a substantial decrease in the intima ratio of the 
L158,809 treated vein grafts compared to the control 
vein grafts. The changes in intimal and medial 
thicknesses occurred consistently through out the 
L158,809 treated vein grafts since there was no 
difference in the intimal ratios of the proximal, middle 
and distal segments. On light and transmission elec- 
tron microscop~ the media demonstrated morpho- 
logical features of hypertrophied smooth muscle cells. 
Subjectivel~ the degree of hypertrophy in these cells 
was less in the L158,809 treated vein grafts. This was 
not caused by a reduction in systemic blood pressure 
during the course of the experiment. In the present 
stud~ L158,809 did not inhibit DNA synthesis or cell 
proliferation in serum stimulated cultured smooth 
muscle cells. Angiotensin II is known to act both as 
mitogenic and hypertrophic agent in smooth muscle 
cells. The decrease in the media suggests that angio- 
tensin II mediated this response in the vein grafts. This 
supposition is further strengthened by the lack of a 
inhibitory response of L158,809 on serum stimulated 
DNA synthesis in smooth muscle cells in vitro in that 
the receptor antagonist did not prevent DNA synthe- 
sis or cell proliferation in the absence of angiotensin II.
The control jugular veins responded to angiotensin II 
with a triphasic dose response curve. This response 
was maintained in the L158,809 treated vein although 
there was a shift of the curve to the right whereas the 
angiotensin II response in the L158,809 treated vein 
grafts was abolished. Treatment with L158,809 does 
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not induce changes in non-angiotensin II induced 
smooth muscle cell contraction in that jugular veins 
and vein grafts harvested from animals treated with 
L158,809 demonstrated nomajor alterations in smooth 
muscle cell contractile responses to norepinephrine 
serotonin and bradykinin. 
Control vein grafts did not respond to acetylcholine 
suggesting that there is endothelial cell dysfunction 
present. However, in contrast in the L158,809 treated 
vein grafts 46% of the rings did respond albeit with 
only a 10% relaxation of precontracted tension. This 
limited preservation of receptor mediated endothe- 
lium-dependent relaxation occurred without signifi- 
cant changes in endothelial cell morphology. In 
response to sodium nitroprusside, a direct smooth 
muscle cell relaxant, there was a marked increase in 
sensitivity of the L158,809 treated vein grafts com- 
pared to control. These findings suggest that the 
presence of the L158,809 may have prevented the total 
loss of receptor-mediated, endothelium dependent 
relaxation. There may be several reasons for this effect: 
a direct effect of the compound on the endothelial 
ceils, an alteration in sensitivity of smooth muscle cell 
relaxation or the significant inhibition of intimal 
hyperplasia. A direct effect on the endothelial cells is 
unlikely as the responses in the control veins and 
L158,809 were unchanged. A direct effect on the 
smooth muscle cells is possible as there are changes in 
the cGMP mediated relaxation of the smooth muscle 
cells by the direct relaxant sodium nitroprusside. 
FinallN the decreased mass of smooth muscle cell in 
both the intima and the media may allow a very weak 
receptor mediated endothelial response to be meas- 
ured on the measuring system employed in this 
study. 
In conclusion, this study suggests that vein grafts 
angiotensin II responses are mediated through an AT~ 
receptor and furthermore, chronic oral treatment with 
L158,809 produced a 48% decrease in intimal cross- 
sectional thickness and a 45% decrease in the medial 
cross-sectional thickness in L158,809 treated vein 
grafts compared to controls. This marked reduction in 
both intimal and medial dimensions by chronic 
L158,809 therapy was associated with the abolition of 
the contractile responses of the vein grafts to angio- 
tensin II. L158,809 does not directly inhibit smooth 
muscle cell DNA synthesis or proliferation. 
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